Lonza Group announces extension of the microbial fermentation plant in Kourim

Production of highly potent active ingredients

29-Jan-2003

Basel - Lonza Group invests CHF 12 million in a further extension in its business sector Lonza Biotec. The existing plant in Kourim (CZ) will be expanded for the custom manufacturing of highly-potent active ingredients based on microbial fermentation.

Therefore a further fermentation line with a capacity of 2 x 15m3 will be constructed. This new plant will enable Lonza to cope with the increasing demand for these ingredients for the Life Sciences Industry. The extension will include special containments to safely handle such potent intermediates and active ingredients. The plant will be operational in the second half of 2003.

Lonza Biotec is focused on microbial fermentation and is the leader in process development and custom manufacturing of therapeutic ingredients and intermediates based on its 20 years of experience. Lonza Biotec undertakes manufacturing services for the pharmaceutical, biotechnology and nutrition industries. With headquarters in Basel (Switzerland), Lonza Biotec operates R&D and cGMP multi-product manufacturing facilities in Visp (Switzerland) and Kourim (Czech Republic).

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances